Triglycerides
90 RCTs · 72,598 participants. The meta-analysis found a dose-response relationship; the effect was more evident above 2 g/day in groups with hyperlipidemia.
html
Cardiovascular evidence spans several areas: risk markers, vascular function, cardiac physiology, imaging and clinical outcomes. The key is to interpret each result in the context of the dose, formulation and population studied.
The figures below come from the cardiovascular presentation, which brings together meta-analyses, randomized trials and imaging studies.
90 RCTs · 72,598 participants. The meta-analysis found a dose-response relationship; the effect was more evident above 2 g/day in groups with hyperlipidemia.
71 trials · 4,973 adults. At 2–3 g/day of EPA+DHA, the average reduction was about 2.6 mmHg systolic and 1.6–1.8 mmHg diastolic.
32 studies · 2,385 participants. Flow-mediated dilation improved on average by +0,8% versus controlo.
51 RCTs · ~3,000 participants. Mean reduction of 2,23 bpm with EPA+DHA e 2,47 bpm in trials using DHA alone.
Cardiovascular effects do not stand alone: they directly intersect with triglycerides, metabolism and liver, with a chronic low-grade inflammation and with the long-term outcomes discussed in longevity and older adults.
Results appear across risk factors, vascular function, cardiac structure and cardiovascular events.
Meta-analyses show a dose-response reduction, with a more evident effect at higher doses and in people with elevated triglycerides.
Average reductions in systolic and diastolic blood pressure were observed in meta-analyses of randomized trials.
Improved flow-mediated dilation, a sign of better blood-vessel response.
Pooled trials showed lower heart rate, especially in studies using DHA.
EVAPORATE and OMEGA-REMODEL showed measurable changes in coronary plaque, remodeling and post-infarction fibrosis.
Large trials and meta-analyses reported reductions in myocardial infarction, coronary events, revascularization and other outcomes in specific populations.
Some trials directly tracked coronary plaque and heart structure.
In 80 statin-treated patients with coronary atherosclerosis and elevated triglycerides, 4 g/day of icosapent ethyl for 18 months reduced low-attenuation plaque volume by 17%; in the placebo group, volume increased 109%.
PMID 32860032 →Related scientific studyIn 358 patients after acute myocardial infarction, six months of high-dose omega-3 were associated with 5,8% additional reduction in left-ventricular end-systolic volume index and 5,6% reduction in non-infarct myocardial fibrosis.
PMID 27482002 →Related scientific studyIn the observational studies brought together in the presentation, higher red-blood-cell EPA+DHA levels were associated with lower cardiovascular risk, including signals from Framingham and pooled cohorts.
Large cohorts and clinical trials converge on a more complete picture of the role of EPA+DHA status in cardiovascular health.
Large trials make it possible to compare results across different doses, formulations and clinical profiles.
RR 0,47 for sudden death at 4 months in 11,323 patients after myocardial infarction.
PMID 11999724 →Related scientific study19% lower major coronary events in the population studied.
PMID 17398308 →Related scientific study25% lower in the primary cardiovascular endpoint with icosapent ethyl in the high-risk population studied.
PMID 30415628 →Related scientific study9% lower total mortality in the heart-failure trial.
PMID 18757090 →Related scientific studyIn VITAL, 25,871 adults received 1 g/day of marine omega-3 and were followed for cardiovascular outcomes.
28% lower (HR 0.72) for total myocardial infarction.
22% less (HR 0.78) for percutaneous coronary intervention.
50% lower (HR 0.50) for fatal myocardial infarction.
VITAL — PMID 30415637 →Related scientific study
The presentation highlights that results become clearer when formulation, dose and population are analyzed separately.
38 RCTs · 149,051 people.
−7% cardiovascular mortality · −13% nonfatal myocardial infarction · −9% coronary events · −9% revascularization.
PMID 34505026 →Related scientific study18 RCTs · 134,144 people.
−10% revascularization · −11% myocardial infarction · −8% cardiovascular death; the presentation highlights a larger magnitude in analyses of purified EPA.
The most useful approach is to combine biomarkers with clinical measures: Omega-3 Index, triglycerides, blood pressure, heart rate and, when indicated, structured medical assessment.
Understand the Omega-3 Index →Triglycerides, blood pressure, endothelial function, resting heart rate, coronary plaque, post-infarction remodeling and cardiovascular events in specific populations.
An appropriate dose, formulation, consistency and enough time to change EPA+DHA status.
Yes. Observational studies found an association between higher red-blood-cell EPA+DHA levels and lower cardiovascular risk, while clinical trials add intervention data.
In addition to the trials above, systematic reviews and large cohorts help place the results on a population scale.
Open the material page to view the visual version, related references and the reviewed PDF for reading or sharing.
Continue from the article to reviewed presentations and return to the topic pages whenever you want to examine the evidence in more depth.